Starkey Jason L, Chiari Estelle F, Isom Harriet C
Department of Microbiology and Immunology, Milton S. Hershey Medical Center, The Penn State University College of Medicine, Hershey, PA 17033, USA.
J Gen Virol. 2009 Jan;90(Pt 1):115-26. doi: 10.1099/vir.0.004408-0.
Hepatitis B virus (HBV) covalently closed circular (CCC) DNA is the source of HBV transcripts and persistence in chronically infected patients. The novel aspect of this study was to determine the effect of RNA interference (RNAi) on HBV CCC DNA when administered prior to establishment of HBV replication or during chronic HBV infection. HBV replication was initiated in HepG2 cells by transduction with HBV baculovirus. Subculture of HBV-expressing HepG2 cells at 10 days post-transduction generates a system in which HBV replication is ongoing and HBV is expressed largely from CCC DNA, thus simulating chronic HBV infection. HepG2 cells were transduced with short hairpin RNA (shRNA)-expressing baculovirus prior to initiation of HBV replication or during chronic HBV replication, and the levels of HBV RNA, HBV surface antigens (HBsAg) and replicative intermediates (RI), extracellular (EC) and CCC DNA species were measured. HBsAg, HBV RNA and DNA levels were markedly reduced until day 8 whether cells were transduced with shRNA prior to or during a chronic infection; however, the CCC DNA species were only affected when shRNA was administered prior to initiation of infection. We conclude that RNAi may have a therapeutic value for controlling HBV replication at the level of RI and EC DNA and for reducing establishment of CCC DNA during HBV infection. Our data support previous findings demonstrating the stability of HBV CCC DNA following antiviral therapy. This study also reports the development of a novel HBV baculovirus subculture system that can be used to evaluate antiviral effects on chronic HBV replication.
乙型肝炎病毒(HBV)共价闭合环状(CCC)DNA是HBV转录本的来源,也是慢性感染患者中病毒持续存在的原因。本研究的新颖之处在于确定RNA干扰(RNAi)在HBV复制建立之前或慢性HBV感染期间给药时对HBV CCC DNA的影响。通过用HBV杆状病毒转导在HepG2细胞中启动HBV复制。转导后10天对表达HBV的HepG2细胞进行传代培养,可产生一个HBV复制持续进行且HBV主要从CCC DNA表达的系统,从而模拟慢性HBV感染。在HBV复制开始之前或慢性HBV复制期间,用表达短发夹RNA(shRNA)的杆状病毒转导HepG2细胞,并测量HBV RNA、HBV表面抗原(HBsAg)和复制中间体(RI)、细胞外(EC)和CCC DNA种类的水平。无论细胞在慢性感染之前还是期间用shRNA转导,直到第8天HBsAg、HBV RNA和DNA水平均显著降低;然而,只有在感染开始之前给予shRNA时,CCC DNA种类才会受到影响。我们得出结论,RNAi可能在控制RI和EC DNA水平的HBV复制以及减少HBV感染期间CCC DNA的建立方面具有治疗价值。我们的数据支持先前的研究结果,即抗病毒治疗后HBV CCC DNA具有稳定性。本研究还报告了一种新型HBV杆状病毒传代培养系统的开发,该系统可用于评估对慢性HBV复制的抗病毒作用。